Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome
Malini Raghavan
Malini Raghavan
Published March 1, 1999
Citation Information: J Clin Invest. 1999;103(5):595-596. https://doi.org/10.1172/JCI6455.
View: Text | PDF
Commentary

Immunodeficiency due to defective antigen processing: the molecular basis for type 1 bare lymphocyte syndrome

  • Text
  • PDF
Abstract

Authors

Malini Raghavan

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Selected components of the MHC class I antigen presentation pathway. The...
Selected components of the MHC class I antigen presentation pathway. The structures of individual components, modes of interaction between the different components, and stoichiometries of binding remain to be fully defined. TAP1 (solid line, striped) and TAP2 (solid line, black) each contain multiple membrane-spanning segments and C–terminal ATP-binding domains, depicted here as L-shaped structures, based upon the crystal structure of analogous domains of a bacterial histidine transporter (15). TAP1 and TAP2 interact to form a functional peptide transporting complex. In the ER lumen, translocated peptides associate with MHC class I heavy chains and β2m (bold dashed lines) (16). Peptide binding by MHC class I molecules is facilitated by the transient formation of TAP–MHC class I complexes. This interaction involves tapasin (dotted lines, gray) as well as calreticulin (2), a cellular chaperone (not shown in the figure). Tapasin interactions with MHC class I molecules may resemble class I interactions with CD8, a coreceptor for the T-cell receptor (17). Defects in either TAP1 or TAP2 result in defective assembly of class I heterodimers and have been shown to cause human MHC class I deficiencies (7, 9, 10). It is likely that other cases of MHC class I deficiencies will map to mutations that interfere with the stable expression of additional components of the MHC class I antigen presentation pathway, or with interactions between the different components.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts